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Abstract 
Background: Inflammation and pain coexist in conditions such as arthritis, inflammatory bowel 
disease, and lower back pain. The drugs currently used to treat the combination of inflammation 
and pain all have disadvantages.  Thus, new drugs and new approaches are needed to treat 
inflammation with pain. The resolvins are considered to be part of the natural resolving 
mechanism for inflammation, and have been shown to prevent inflammation in animal models. 
Objectives/methods: To evaluate a paper suggesting that the resolvins RvE1 and RvD1 attenuate 
inflammatory pain in animal models.  Results: RvE1 has been shown to attenuate inflammation 
and, to a lesser extent, pain in animal models.  Limited results are presented of the effectiveness 
of RvD1 against inflammatory pain. Conclusion: Drugs that mimic or potentiate the effects of the 
resolvins may be useful for the treatment of some inflammation with pain. 











Inflammation and pain coexist in conditions such as arthritis, inflammatory bowel disease, and 
lower back pain.  Of these, mechanical low back pain is the second most common symptom-
related reason for seeing a physician in the United States, and occurs at least once in 85% of 
adults below the age of 50.  Nearly all of them will have at least one recurrence.  About 1% of the 
world's population is afflicted by rheumatoid arthritis with women being affected three times more 
often than men.  Another 1% of the population is affected by osteoarthritis.  Like low back pain, 
arthritis is a leading cause of disability.  Inflammatory bowel disease is less common (0.2%).  
However, inflammatory bowel disease reduces quality of life greatly by causing pain, diarrhea and 
vomiting.  
 
The drugs most commonly used to treat a combination of inflammation and pain are the 
cyclooxygenase (COX) inhibitors.  These are only effective in mild-to-moderate inflammation and 
pain.  When inflammation is severe, the glucocorticoids are often needed to decrease the 
inflammation, and when pain is severe, the opioids may be used to decrease pain.  All of these 
drugs have disadvantages.  Notably, non-selective COX inhibitors cause gastrointestinal 
bleeding, and the COX-2 selective inhibitors increase the risk of cardiovascular disease.  The 
glucocorticoids are not suitable for the long term systemic use in chronic inflammation, as they 
cause a wide range of side effects on chronic use. The opioids cause drowsiness, constipation, 
nausea, sedation, and cognitive disturbances.  Thus, there is a need for new drugs that are useful 
in the treatment of conditions associated with a combination of inflammation and pain.  
 
Diets supplemented with omega-3 polyunsaturated fatty acids (ω-3 PUFAs) have been suggested 
to have antiinflammatory actions.  These actions of ω-3 PUFAs may be useful in the treatment of 
inflammatory conditions such as arthritis, inflammatory bowel disease, and cardiovascular 
disease [1].  Notably in cardiovascular disease, the Gruppo Italiano per lo Studio della 
Sopravvivenza nell’Infarto Miocardico-Prevenzione trial enrolled subjects who had a recent 
myocardial infarction and showed that there was a reduction in mortality with ω-3 PUFAs [2].   
 
Recently, studies have been undertaken to determine the cellular and molecular mechanisms of 
the antiinflammatory effects of ω-3 PUFAs. Serhan et al showed that the inflammatory exudates 
from mice treated with ω-3 PUFAs and aspirin generated a novel array of bioactive lipid signals 
[3], and these signals have been named resolvins.  The resolvins are discussed more in the next 
section, and then there is an evaluation of a recent paper discussing the antiinflammatory and 
analgesic properties of resolvins in animal models of inflammatory pain, and the mechanism of 




2. Resolvins – the story so far 
The resolvins are derived from ω-3 PUFAs and are part of the natural resolving mechanism for 
inflammation.  The levels of resolvins can be increased by increasing the levels of the ω-3 
PUFAs.  The major ω-3 PUFAs are eicosapentaenoic acid (EPA) and docosahexaenoic acid 
(DHA).  When cyclooxygenase-2 (COX-2) is inhibited with aspirin, EPA is metabolised by a 
pathway involving lipooxygenase (LOX) to RvE1 (5S,12R,18R-trihydroxy-6Z,8E,14Z,16E- 
eicosapentaenoic acid) and RvE2 (5S, 18-dihydroxyeicosapentaenoic acid) [5].  The resolvin D 
series are formed from DHA and also use the LOX pathway [5].  RvE1 and RvE2 can also be 
formed from EPA by p450 pathway in human polymorphonuclear leukocytes [5].  RvE1 is present 
in human plasma, and the levels of RvE1 are increased by taking aspirin [5].  RvD1 is generated 
from DHA in human blood [6].  
 
The effects of RvE1 are mediated by a G-protein-coupled receptor, GPCR ChemR23, and leads 
to the attenuation of nuclear factor (NF)-κB [5].  The effects of RvD1 are probably mediated by 
two receptors; ALX, a lipoxin A4 receptor and another GPCR, GPR32 [7].  Activation of the 
receptors leads to a reduction in tumour necrosis factor (TNF)-α-stimulated NF-κB [7].  RvD1 had 
no effect at the RvE1 receptor ChemR23 [7].    
 
In animal models of inflammation (periodontal disease, colitis, retinal neovascularisation), RvE1 
has been shown to protect against inflammation [5].  RvE1 has also been shown to dampen 
airway inflammation and hyperresponsiveness in a mouse model of asthma [8].  Recently, RvE1 
has been shown to protect the rat heart against reperfusion injury [9].  In these experiments, 
RvE1 was administered after the ischemia but prior to the reperfusion and was shown to reduce 
infarct size [9].   
 
Cerebral ischemia produced by cerebral artery in mice is used as a model of ischaemic stroke, 
and in this model RvD1 is produced, and the administration of RvD1 into the ventricles reduces 
leukocyte polymorphonuclear infiltration into the brain [10].  Similarly, in peritonitis, RvD1 reduces 
polymorphonuclear infiltration [11].  RvD1 is produced by mouse kidneys in response to 
ischemia/reperfusion injury [12].  Administration of RvD1 before the ischemia or 10 minutes after 
the reperfusion reduced the damage to the kidney [12].   
 
3. Resolvins – latest findings 
3.1 Methods and results 
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The methods and results of the paper showing that resolvins may be useful in the treatment of 
inflammatory pain [4] are summarised in this section.  As an acute model of inflammation, 
injection of formalin into the feet of mice (intraplantar) produces immediate and secondary pain, 
and the secondary pain is due to central mechanisms.  When RvE1 at 0.3 and 1 ng was injected 
into the mouse spine intrathecally, it had no effect on the immediate pain, but inhibited the 
secondary pain, and in doing so, was equieffective to morphine at 100 ng, and to NS-398 (a 
COX-2) inhibitor at 10 μg. This shows that RvE1 is more potent than morphine or NS-398 at 
inhibiting the secondary pain in this model.  This also suggests that RvE1 inhibits pain by a 
central mechanism.   
 
The G protein subunit Gαi is probably associated with the ChemR23 receptor for RvE1, and 
inhibition of this subunit with pertussis toxin, reduced the analgesic response to RvE1 in the 
formalin model.  This result shows the involvement of the Gαi subunit in the response to RvE1.  
Chemerin, which is a peptide agonist at ChemR23, reduced the secondary pain response in the 
formalin model, which shows that the analgesic response can be mediated via ChemR23.  The 
opioid antagonist naloxone reduced the analgesic response to morphine, but not to RvE1, and 
this shows that the analgesic response to morphine, but not to RvE1, is mediated by opioid 
receptors.  Knockout of ChemR23 with siRNA abolished the analgesic response to RvE1, which 
is a good demonstration that the analgesic effect of RvE1 is mediated by ChemR23. 
 
Localisation studies showed that ChemR23 mRNA was found in the dorsal route ganglion and 
neurons, and in the spinal cord and the primary afferent terminals of this.  Thus, the receptors are 
located in regions, which support central mechanisms of action for RvE1.  
 
As a model of persistent inflammation, complete Freund’s adjuvant was injected into the feet of 
mice.  In this model the pain and inflammation lasts for weeks, and the intrathecal administration 
of resolvins reduced the hyperalgesia response to heat.  For instance, 10 ng of RvE1 inhibited the 
hyperalgesia by about 75%.  RvE1 was also more potent that the COX-2 inhibitor NS-398 in this 
model.  A stable analog of RvE1 that is resistant to metabolic breakdown, 19-(p-fluorophenoxy)-
RvE1, caused a prolonged (6 hour) reduction in hyperalgesia.  Much higher concentrations of the 
precursors of RvE1 and RvF1, eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), 
respectively, than the resolvins, were needed to inhibit the hyperalgesia.   
 
As a model of chronic inflammation, carrageenan was injected into the feet of mice, and this 
caused pain and inflammation.  Intraplantar pretreatment with RvD1 or RvE1 reduced the heat 
hyperalgesia response in these mice.  RvE1 reduced the carrageenan-induced oedema and 
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neutrophils infiltration.  RvE1 also reduced the expression of the cytokines; tumour necrosis 
factor-α (TNF-α), interleukin-1β (IL-1 β) and IL-6, and the expression of the chemokines; 
monocyte chemotatic protein-1 and macrophage inflammatory protein-1α.  As intraplantar 
administration of resolvins was effective in this model, it suggests that peripheral mechanisms are 
involved in the analgesic response.  In support of this, intraplantar administration of RvE1 also 
reduced formalin-induced acute pain in the mouse. 
 
TNF-α is major contributor to both pain and inflammation, and it does this by both central and 
peripheral mechanisms.  Transient receptor potential vanilloid subtype-1 (TRPV1) is 
predominantly found on sensory neurones where it has an important role in pain transmission.  
The formalin-elicited and complete Feund’s adjuvant models of pain and inflammation are much 
reduced in TNF-α knockout mice.  Intrathecal TNF-α induces heat hyperplasia in mice, which is 
reduced by spinal administration of RvE1.  The response to TNF-α is not present in mice lacking 
the gene for TRPV1, which implicated TRPV1 in the response to TNF-α.  The pain and 
inflammatory response to formalin is observed in TRPV1 knockout mice, as this response is 
inhibited by RvE1, and this suggests that TRPV1-independent mechanisms are also involved in 
the antiinflammatory effects of RvE1.   
 
Further experiments supported the involvement of both TNF-α and TRPV1 in the 
antiinflammatory actions of RvE1.  In patch-clamp studies in spinal cord slices from mice, there 
were spontaneous excitatory postsynaptic currents in the lamina II neurones, and the frequency, 
but not the amplitude, of these was increased by TNF-α.  This response to TNF-α was abolished 
by the TRPV1 antagonist capsazepine, and by RvE1.  RvE1 also reduced the increased 
frequency due to the administration of the TRPV1 agonist capsaicin.  Chemerin also abolished 
the response to capsaicin, which suggests the involvement of ChemR23.  Intrathecal capsaicin 
induced acted pain in the mouse, and this was prevented by intrathecal RvE1.  Intraplantar 
capsaicin also induced pain, and this was reduced by peripheral RvE1. 
 
In the complete Freund’s adjuvant model and after intrathecal TNF-α in the mouse, mechanical 
allodynia (a reduction in paw withdrawal threshold) is also observed, and RvE1 (administered 3 
days after the adjuvant) reduced this response.  Increased activity of the glutamate NMDA 
receptors on dorsal horn neurones is associated with mechanical allodynia.  In preparations of 
these neurones, TNF-α increased the NMDA currents, and RvE1 reversed this.   
 
In a mouse model of nerve injury/spinal nerve ligation-induced neuropathic pain, post-treatment 
with RvE1 caused a small reduction in the paw withdrawal latency.  RvD1 was tested in a mouse 
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model of chronic pain (incision-induced postoperative pain) and intraplantar pretreatment was 
shown to be effective.   
  
3.1 Discussion 
The authors concluded that resolvins may represent a new family of analgesic useful in treating 
inflammation-associated pain states such as arthritic and post-operative pain [4]. 
 
4 Expert opinion 
 
4.1 Are resolvins underactive in excessive inflammation? 
As the resolvins have only recently been discovered, we are at the early stages of characterising 
their physiological and pathophysiological roles.  Much more needs to be done in this area, and 
one of the interesting questions is whether the resolvin system is underactive in reducing 
inflammation in some pathophysiological conditions associated with excessive inflammation.  If 
this was the case, bolstering the levels of resolvins by administering ω-3 PUFAs would be a 
logical approach to treating excessive inflammation.  Drugs that increase the levels or mimic the 
effects of resolvins may be a new approach to the treatment of conditions associated with 
excessive inflammation (e.g. rheumatoid arthritis, inflammatory bowel disease).  
 
4.2 Can we extrapolate from RvE1 to RvD1? 
The authors of the paper on RvE1 and RvD1 seem to be extrapolating the results with one of the 
resolvins to the other.  From reading the published manuscript and supplementary information, 
the authors have shown that RvE1 is effective against the formalin model of acute inflammation, 
the complete Freund’s adjuvant model of persistent inflammation, the carrageenan model of 
chronic inflammation, TNF-α-induced heat hyperplasia, and nerve injury/spinal nerve ligation-
induced neuropathic pain.  RvD1 was shown to be effective in the mouse carrageenan model and 
the model of chronic pain (incision-induced postoperative pain), but data was not shown or 
claimed for other models.  However, from this data, the authors seem to me to be suggesting that 
both RvE1 and RvD1 have similar abilities to attenuate inflammatory pain when they have only 
presented data for RvD1 in chronic inflammation (not acute or persistent inflammation), and have 
not presented data for RvE1 in their model of postoperative pain.  Until the results for both 
resolvins in all the models are presented, this seems to me, to be an extravagant claim. 
 
4.3 Persistent and chronic inflammation 
To be useful in relieving persistent and chronic inflammation, drugs need to be effective when 
administered after the chronic inflammation has developed.  In the model of persistent 
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inflammation, Complete Freund’s adjuvant in mice, resolvins were effective when administered 3 
days after the adjuvant.  The ongoing effects of resolvins in adjuvant inflammation need to be 
assessed.  In chronic inflammation, the resolvins, RvE1 and RvD1, are only reported to inhibit the 
heat hyperalgesia response in mice, when they are administered before the carrageenan.  The 
effects of resolvins, after the development of carrageenan-induced pain and inflammation, needs 
to be studied and reported.  The resolvins will only be useful in the treatment of persistent or 
chronic inflammation, if they are effective on an ongoing basis after the establishment of the 
inflammation. 
 
4.4 Potency as analgesics 
As pointed out by Sommer & Birklein ([13]), the effect of the resolvins on TNF-induced pain is 
moderate, and this casts doubt as whether drugs that mimic resolvins will be useful analgesics 
[13].  To support this assertion, they cited that the drug lacosamide, which had stronger effects 
than the resolvins in an animal model of pain induced by TNF [14], had failed in clinical trial by 
giving similar responses to placebo in painful diabetic neuropathy [15].  In the study of 
lacosamide in an animal model of pain induced by TNF, lacosamide was more potent than 
gabapentin and pregabalin [14].  Gabapentin and pregabalin have been shown to be useful in 
painful diabetic neuropathy [16].  This suggests that there is no direct correlation between TNF-
induced pain animal models and effects in painful diabetic neuropathy.   Clearly, further studies of 
resolvins in other animal models of pain are needed as we continue to assess whether they will 
be powerful and/or useful analgesics in a variety of painful conditions. 
 
4.5 Conclusions 
We are at the early stages of characterising the physiological and pathophysiological roles of 
resolvins.  There is good evidence that RvE1 can reverse inflammation whereas there is less 
testing with RvD1.  Diets or drugs that increase the levels of RvE1, and drugs that mimic the 
effects of RvE1 or prevent the breakdown of RvE1 may be useful in the treatment of 
inflammation.  More evidence is required to support an analgesic effect of the resolvins.  
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